Bob DiNello

Bob DiNello has a long and varied career in the field of diagnostics development. Bob began their career in 1984 as the Director of Diagnostics Development at Chiron Corporation. In 1998, they moved to PraxSys Biosystems as the Vice President of Research and Development. In 2002, they became the Director of Assay Development at TriPath Oncology, where they managed the clinical trial of the SurePath sample in the Digene HPV assay. In 2004, they moved to ReLIA Diagnostic Systems as the VP of R&D, where they resided in China and headed R&D and Manufacturing at the Chinese subsidiary. In 2009, they became the Chief Technical Officer at Health-Chem Diagnostics LLC. In 2011, they moved to Silver Lake Research as the Director of Diagnostics Development. Finally, in 2018, they became the Director of Diagnostics Development at Evergreen Sciences, Inc. and in 2019, they moved to FemtoDx as the Director of Assay Development.

Bob DiNello obtained a BS in Biology from Yale University and a PhD in Biological Chemistry from Harvard University.